Clinical Trials Actively Recruiting

Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below.

Results 1 - 10 of 199

  • Objective:
    Primary Objective:
    • To compare the progression-free survival (PFS) in patients with newly diagnosed advanced stage classical Hodgkin lymphoma randomized to N-AVD (nivolumab, doxorubicin, vinblastine, dacarbazine) versus that obtained with BV-AVD (brentuximab vedotin, doxorubicin, vinblastine, dacarbazine).
    Secondary Objectives:
    • To compare overall survival (OS) in patients randomized to N-AVD versus BV-AVD.
    • To compare event-free survival (EFS) in patients randomized to N-AVD versus BV-AVD.
    • To compare the metabolic complete response (CR) rate at the end of treatment in patients randomized to N-AVD versus BV-AVD.
    • To compare the physician-reported treatment-related adverse event rates between arms stratified by age groups.
    • To compare patient-reported symptoms using selected PRO-CTCAE items between arms stratified by age groups.
    • To compare the safety and tolerability of N-AVD versus that of BV-AVD.
    Cancer Categories:
    • Hematologic (Blood Cancers)
    Principal Investigator:
    • Sano, Dahlia
    Karmanos Trial ID:
    • S1826
    Age Group:
    • Both
    Phase:
    • Phase III
  • Objective:
    Primary Objective:
    • To evaluate the efficacy of trastuzumab and pertuzumab (TP) in HER-2 amplified metastatic colorectal cancer (mCRC) by comparing progression-free survival (PFS) on TP compared to control arm of cetuximab and irinotecan (CETIRI).
    Secondary Objectives:
    • To evaluate the overall response rate (ORR), including confirmed complete and partial response per RECIST 1.1, in the TP and CETIRI treatment arms.
    • To evaluate the overall survival (OS) in the TP and CETIRI treatment arms.
    • To evaluate the safety and toxicity of TP compared to CETIRI.
    Cancer Categories:
    • Gastrointestinal (GI)
    Principal Investigator:
    • Tesfaye, Anteneh
    Karmanos Trial ID:
    • S1613
    Age Group:
    • Adult
    Phase:
    • Phase II
  • Objective:
    Primary:
    To compare invasive disease-free survival (IDFS) of patients with triple-negative breast cancer (TNBC) who have either >1 cm residual invasive breast cancer and/or positive lymph nodes (>ypN+) after neoadjuvant chemotherapy randomized to receive 1 year of MK-3475 (pembrolizumab) adjuvant therapy compared to no MK-3475 (pembrolizumab), in both the entire study population and also in the PDL1 positive subset.
    Secondary:
    1. To compare the effects of MK-3475 (pembrolizumab) on overall survival (OS) and distant recurrence-free survival (DRFS) between the two randomized arms for the PD-L1 positive patients and then all patients.
    2. To assess the toxicity and tolerability of MK-3475 (pembrolizumab) in this patient population with or without radiation therapy.
    Cancer Categories:
    • Breast
    Principal Investigator:
    • Flaherty, Lawrence
    Karmanos Trial ID:
    • S1418
    Age Group:
    • Adult
    Phase:
    • Phase III
  • Objective:
    Primary Objective:
    • To compare bladder intact event-free survival (BI-EFS) for concurrent chemoradiation therapy (CRT) with and without atezolizumab in localized muscle invasive bladder cancer (MIBC).
    Secondary Objectives:
    • To compare overall survival between the two arms.
    • To compare modified bladder intact event-free survival (mBI-EFS see Section 10) including cancer related death between arms.
    • To compare complete and partial pathologic response between arms at 3 months after completing chemoradiation therapy.
    • To estimate metastases-free survival by arm.
    • To compare the qualitative and quantitative adverse events from each arm.
    • To estimate the rate of non-muscle invasive bladder cancer recurrence by arm.
    • To estimate the rate of salvage cystectomy and reasons for cystectomy by arm.
    • To compare mean patient-reported global quality of life (QOL) at week 54 using the EORTC QLQ-C30 Global Health Status (GHS) subscale score between patients with localized muscle-invasive bladder cancer randomized to chemoradiation with vs. without atezolizumab.
    Cancer Categories:
    • Genitourinary (GU)
    Principal Investigator:
    • Vaishampayan, Nitin
    Karmanos Trial ID:
    • S1806
    Age Group:
    • Adult
    Phase:
    • Phase III
  • Objective:
    Primary Objective:
    • To compare overall survival (OS) between the two treatment arms with lenalidomide as the comparator arm and lenalidomide + daratumumab/rHuPH20 as the experimental arm in post-autologous transplant multiple myeloma (MM) patients.
    Secondary Objectives of First Randomization:
    • To compare the best overall response rate (ORR), including partial remission (PR), very good partial remission (VGPR), and complete remission (CR, sCR) in the subset of patients not in PR at randomization to lenalidomide versus lenalidomide + daratumumab/rHuPH20 in this patient population.
    • To compare progression-free survival (PFS) between the study arms in this patient population.
    • To evaluate MRD-negativity on the two treatment arms at randomization (Registration Step 2), and to compare MRD-negativity rate at 12, 24 (second randomization), 36, and 48 months after first randomization between lenalidomide and lenalidomide + daratumumab/rHuPH20 in this patient population.
    • To compare toxicities and tolerability of long term therapy between the study arms.
    Objectives of Second Randomization:
    • To compare overall survival (OS) between MRD negative patients randomized to continued lenalidomide vs. discontinued lenalidomide from the time of second randomization in this patient population.
    • To compare overall survival (OS) between MRD negative patients randomized to continued lenalidomide + daratumumab/rHuPH20 vs. discontinued lenalidomide + daratumumab/rHuPH20 from time of second randomization in this patient population.
    Cancer Categories:
    • Hematologic (Blood Cancers)
    Principal Investigator:
    • Kin, Andrew
    Karmanos Trial ID:
    • S1803
    Age Group:
    • Adult
    Phase:
    • Phase III
  • Objective:
    Primary Objective(s):
    • To assess whether prophylactic beta blocker therapy with carvedilol compared with no intervention reduces the risk of subsequent cardiac dysfunction in patients with metastatic breast cancer receiving trastuzumab?based HER-2 targeted therapy.
    Secondary Objective(s):
    • To assess whether prophylactic beta blocker therapy with carvedilol compared with no intervention reduces the risk of predefined subsequent cardiac events in patients with metastatic breast cancer receiving trastuzumab?based HER-2 targeted therapy.
    • To evaluate if prophylactic carvedilol compared with no intervention results in a longer time to first interruption of trastuzumab?based HER-2 targeted therapy due to either cardiac dysfunction or events.
    • To assess whether prophylactic beta blocker therapy with carvedilol compared with no intervention reduces the risk of subsequent cardiac dysfunction OR events in this population.
    • To establish and prospectively collect a predefined panel of baseline core cardiovascular measures and develop a predictive model of cardiac dysfunction (see Section 11.2).
    • To evaluate the rate of cardiac dysfunction in an observational arm consisting of individuals otherwise eligible for the study except for use of beta blockers, angiotensin receptor blocker (ARB), or angiotensin converting enzyme (ACE) inhibitors for other medical reasons.
    Cancer Categories:
    • Breast
    Principal Investigator:
    • Assad, Hadeel
    Karmanos Trial ID:
    • S1501
    Age Group:
    • Adult
    Phase:
    • Phase III
  • Objective:
    Primary Objectives
    1. To evaluate whether progression-free survival (PFS) meets an efficacy threshold in patients with previously treated advanced small bowel adenocarcinoma who receive treatment with ramucirumab and paclitaxel or FOLFIRI.
    2. If the stated threshold is met in both arms, to choose the better regimen with respect to PFS.

    Secondary Objectives
    1. To assess overall response rate (ORR) [complete and partial, confirmed and unconfirmed] in the subset of patients with measurable disease treated with ramucirumab and paclitaxel or FOLFIRI in this patient population.
    2. To assess overall survival (OS) in patients treated with ramucirumab and paclitaxel or FOLFIRI in this patient population.
    3. To evaluate safety and toxicity associated with combination ramucirumab and paclitaxel treatment or FOLFIRI therapy in this patient population.
    Cancer Categories:
    • Gastrointestinal (GI)
    Principal Investigator:
    • Shields, Anthony
    Karmanos Trial ID:
    • S1922
    Age Group:
    • Adult
    Phase:
    • Phase II
  • Objective:
    Primary Objective:
    • The primary goal of this study is to determine whether, in men with post-prostatectomy PSA (prostate specific antigen) recurrences with aggressive disease features, salvage radiotherapy (SRT) with enhanced androgen deprivation therapy (ADT), consisting of enzalutamide (MDV3100) and a GnRH analog, will improve progression-free survival compared to SRT with standard GnRH analog -based ADT.
    Secondary Objectives:
    • To compare the rates of biochemical failure, an alternative biochemical failure endpoint, hormone-refractory disease (HRD), distant metastasis, cause-specific mortality, and overall mortality between patients who receive SRT with standard GnRH analog-based ADT and those who receive SRT with enhanced ADT.
    • To compare acute and late physician- and patient-reported toxicity between patients who receive SRT with standard GnRH analog-based ADT and those who receive SRT with enhanced ADT.
    • To compare fatigue using the PROMIS-F SF 7a between patients who receive SRT with standard GnRH analog-based ADT and those who receive SRT with enhanced ADT.
    • To assess global quality of life using the EQ-5D-5L between patients who receive SRT with standard GnRH analog-based ADT and those who receive SRT with enhanced ADT.
    Cancer Categories:
    • Genitourinary (GU)
    Principal Investigator:
    • Bhatt, Amit
    Karmanos Trial ID:
    • RTOG3506
    Age Group:
    • Adult
    Phase:
    • Phase II
  • Objective:
    Primary Objective
    To compare the non-inferiority of bilateral salpingectomy (BLS) with delayed oophorectomy to bilateral salpingo-oophorectomy (BSO) to reduce the risk of ovarian cancer among women with deleterious BRCA1 germ-line mutations.

    Secondary Objectives
    • To prospectively assess estrogen deprivation symptoms in BLS patients as measured by the FACTES sub-scale compared to women in the BSO arm.
    • To determine if health-related QOL (FACT) is negatively impacted by menopausal symptoms (menopausal symptom checklist-MSCL), sexual dysfunction (FSFI), and cancer distress (IES) in women who have undergone BLS, in comparison to normative data (MSCL/FACT-ES) and data from BSO patients.
    • To assess medical decision making, as measured by the Shared Decision Making Questionnaire (SDM-Q-9) and Decision Regret Scale (DRS), and determine factors associated with the risk of reducing surgical treatment choice.
    • To assess adverse events, graded using CTCAE v5.0.
    Cancer Categories:
    • Gynecologic
    Principal Investigator:
    • Winer, Ira
    Karmanos Trial ID:
    • NRG-CC008
    Age Group:
    • Adult
    Phase:
    • NA
  • Objective:
    Primary
    To compare the 3-year recurrence-free survival of women with high intermediate risk (HIR) Stage I/II mismatch repair deficient (dMMR) endometrioid endometrial cancer treated with radiation and MK-3475 (pembrolizumab) versus radiation alone.

    Secondary Objectives
    1. To describe the safety and tolerability of concurrent MK-3475 (pembrolizumab) and radiation compared to radiation alone in patients with MMR deficient high intermediate risk endometrial cancer (HIR EC).
    2. To describe the recurrence patterns in each group.
    3. To measure recurrence free survival at 5 years in each group.
    4. To estimate disease specific overall survival in each group.
    5. To determine whether the addition of MK-3475 (pembrolizumab) to radiation, compared with radiation alone is associated with decreased quality of life at 6- and 24-weeks, as measured with the FACT-En TOI, increased GI symptoms as measured with the GI subscale, and increased fatigue as measured with the PROMIS-Fatigue scale (short form).
    6. To validate the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM) subscale, which assesses in cancer patients on immunotherapy.


    Cancer Categories:
    • Gynecologic
    Principal Investigator:
    • Gogoi, Radhika
    Karmanos Trial ID:
    • NRG-GY020
    Age Group:
    • Adult
    Phase:
    • Phase III